Fujifilm Holdings is the biotechnology company most prolific at making international expansions, followed by Danaher and Beijing BGI-GBI Biotech. GlobalData’s biotechnology foreign direct investment (FDI) company report highlights the current foreign investments made by leading biotechnology investors. Buy the report here.
Fujifilm Holdings has been the most active biotechnology greenfield investor between Q1 2019 and Q3 2023, according to GlobalData’s FDI Projects Database.
Greenfield foreign direct investment is when a company invests abroad to establish a new physical presence or expand an existing operation. Greenfield investments create jobs and/or involve a capital investment into the foreign location. Other forms of FDI, such as mergers and acquisitions, are not included as part of this definition.
The majority of Fujifilm Holdings investments were in the genomics subsector. In fact, 21.6% of its total foreign investments were in this subsector. It also created projects across a further 13 subsectors.
The company has been active across six world regions, mainly focused on North America which received 37.3% of the company’s greenfield investments between Q1 2019 and Q3 2023. Its top three destination countries (by number of greenfield FDI projects) were the US, the UK and India. Combined these three countries account for 164.7% of its total number of biotechnology investments.
Fujifilm Holdings created more FDI projects in 2021 compared to any other year between Q1 2019 and Q3 2023.
The US is the leading source market for outbound biotechnology greenfield FDI projects. The country accounts for 29.8% of total outbound biotechnology investment projects. There have been 92 unique parent companies from the US that have announced biotechnology FDI projects between between Q1 2019 and Q3 2023.
To further understand the top biotechnology FDI companies, access GlobalData’s Top biotechnology Foreign Direct Investment Companies report.